{"id":560781,"date":"2026-08-04T22:52:09","date_gmt":"2026-08-04T20:52:09","guid":{"rendered":"https:\/\/medizinonline.com\/?p=560781"},"modified":"2026-08-04T22:52:23","modified_gmt":"2026-08-04T20:52:23","slug":"le-premier-inhibiteur-de-laldosterone-synthase-est-desormais-disponible","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/le-premier-inhibiteur-de-laldosterone-synthase-est-desormais-disponible\/","title":{"rendered":"Le premier inhibiteur de l&#8217;aldost\u00e9rone synthase est d\u00e9sormais disponible"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Il s&#8217;agit de la premi\u00e8re nouvelle classe de principes actifs antihypertenseurs depuis des ann\u00e9es : le 18 mai 2026, l&#8217;agence am\u00e9ricaine de r\u00e9glementation des m\u00e9dicaments (FDA) a autoris\u00e9 le Baxdrostat (Baxfendy) en tant que premier et unique inhibiteur de l&#8217;aldost\u00e9rone synthase destin\u00e9 au traitement de l&#8217;hypertension. Cette substance s&#8217;attaque \u00e0 l&#8217;une des causes profondes de l&#8217;hypertension difficile \u00e0 contr\u00f4ler \u2013 la production excessive d&#8217;aldost\u00e9rone \u2013 et abaisse la tension art\u00e9rielle l\u00e0 o\u00f9 les traitements \u00e9tablis atteignent souvent leurs limites. Cette autorisation s&#8217;appuie sur l&#8217;\u00e9tude de phase III BaxHTN, compl\u00e9t\u00e9e par l&#8217;\u00e9tude Bax24 portant sur la mesure de la pression art\u00e9rielle sur 24 heures chez les patients atteints d&#8217;hypertension r\u00e9sistante. Avec le lorundrostat, deuxi\u00e8me inhibiteur de l\u2019aldost\u00e9rone synthase, et le zilebesiran, une approche bas\u00e9e sur l\u2019ARN, toute une vague de nouveaux principes th\u00e9rapeutiques se profile.     <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fle-premier-inhibiteur-de-laldosterone-synthase-est-desormais-disponible%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Il s&#8217;agit de la premi\u00e8re nouvelle classe de principes actifs antihypertenseurs depuis des ann\u00e9es : le 18 mai 2026, l&#8217;agence am\u00e9ricaine de r\u00e9glementation des m\u00e9dicaments (FDA) a autoris\u00e9 le Baxdrostat&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fle-premier-inhibiteur-de-laldosterone-synthase-est-desormais-disponible%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560782,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Le Baxdrostat : une nouvelle classe de m\u00e9dicaments contre l'hypertension difficile \u00e0 contr\u00f4ler","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11378,11527,11531,11315,11464],"tags":[95525,40539,95526],"powerkit_post_featured":[],"class_list":["post-560781","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-cardiologie","category-etudes","category-formation-continue","category-medecine-interne-generale","category-pharmacologie-et-toxicologie","tag-baxdrostat","tag-hypertension-fr-2","tag-inhibiteurs-de-laldosterone-synthase","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-23 15:39:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":560784,"slug":"e-disponibile-il-primo-inibitore-dellaldosterone-sintasi","post_title":"\u00c8 disponibile il primo inibitore dell'aldosterone sintasi","href":"https:\/\/medizinonline.com\/it\/e-disponibile-il-primo-inibitore-dellaldosterone-sintasi\/"},"pt_PT":{"locale":"pt_PT","id":560787,"slug":"chegou-o-primeiro-inibidor-da-aldosterona-sintase","post_title":"Chegou o primeiro inibidor da aldosterona sintase","href":"https:\/\/medizinonline.com\/pt-pt\/chegou-o-primeiro-inibidor-da-aldosterona-sintase\/"},"es_ES":{"locale":"es_ES","id":560790,"slug":"ya-esta-disponible-el-primer-inhibidor-de-la-aldosterona-sintasa","post_title":"Ya est\u00e1 disponible el primer inhibidor de la aldosterona sintasa","href":"https:\/\/medizinonline.com\/es\/ya-esta-disponible-el-primer-inhibidor-de-la-aldosterona-sintasa\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=560781"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560781\/revisions"}],"predecessor-version":[{"id":560783,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/560781\/revisions\/560783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/560782"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=560781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=560781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=560781"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=560781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}